Avalo Therapeutics, Inc. (AVTX) has 13 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 2 sales totalling $2.2M. Most recent filing: Sept. 18, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 18, 2026 filed Sept. 16, 2026 | Sullivan Christopher Ryan Chief Financial Officer | $79,985 | 37,182 | 0% | Yes | |
|
|
||||||
| Sept. 11, 2026 filed Sept. 10, 2026 | Sullivan Christopher Ryan Chief Financial Officer | $97,569 | 30,555 | 0% | Yes | |
|
|
||||||
| Sept. 1, 2026 filed Aug. 28, 2026 | Doyle Mittie Chief Medical Officer | $8,121 | 2,037 | 0% | Yes | |
|
|
||||||
| Aug. 19, 2026 filed Aug. 17, 2026 | Sullivan Christopher Ryan Chief Financial Officer | −$17,411 | 216,429 | −1% | Yes | |
|
|
||||||
| Aug. 19, 2026 filed Aug. 17, 2026 | Doyle Mittie Chief Medical Officer | $7,350 | 3,000 | 0% | Yes | |
|
|
||||||
Showing the 5 most recent of 13 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free